Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Praliciguat (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAPACITY-HFpEF
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 15 Aug 2018 Planned number of patients changed from 332 to 184.
    • 06 Aug 2018 According to an Ironwood Pharmaceuticals media release, Topline data from this study are expected in the second half of 2019.
    • 02 Nov 2017 Status changed from not yet recruiting to recruiting, according to an Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top